Summary & Overview
HCPCS Level II J1438: Etanercept 25 mg Injection, Physician-Administered
HCPCS Level II code J1438 identifies a 25 mg injection of etanercept administered under physician supervision and not intended for patient self-administration. This designation matters nationally because it distinguishes clinic- or office-administered biologic therapy from self-injectable drug claims, affecting billing pathways, site-of-service classification, and Medicare coverage rules. The code is commonly encountered in rheumatology and dermatology practices that provide parenteral biologic treatments.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J1438 represents clinically and operationally, plus guidance on typical sites of service and service type. The publication summarizes relevant benchmarks, payer coverage patterns, and recent policy considerations that influence how payers process physician-administered biologic injections. It also provides clinical context about etanercept as a parenteral biologic and practical implications for coding and claims workflows.
Where input data was not provided, the report notes those fields as unavailable and focuses on the available national-level coding and service information.
Billing Code Overview
HCPCS Level II code J1438 represents the injection of etanercept, 25 mg. The code description specifies that it may be used for Medicare when the drug is administered under the direct supervision of a physician and is not for use when the drug is self-administered.
Service Type: Drug administration (injectable biologic)
Typical Site of Service: Physician office or outpatient clinic where parenteral biologic therapy is administered under direct physician supervision
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient with moderate to severe rheumatoid arthritis presents to an outpatient physician office for administration of biologic therapy. The clinician prescribes etanercept 25 mg injections to be administered in clinic under direct physician supervision because the patient requires evaluation for injection-related reactions and the payer (for example, Medicare) requires facility/physician-administered billing rather than self-administration. The clinical workflow includes verification of identity and consent, review of recent labs for infection risk, medication preparation by licensed staff, administration of J1438 (etanercept 25 mg) via subcutaneous injection, observation for immediate adverse reactions for 15–30 minutes, documentation of lot number and site, and billing the drug under the HCPCS Level II code J1438. Typical site of service is an outpatient physician office or hospital outpatient department. The patient may have comorbidities such as diabetes or chronic lung disease that require closer post-injection monitoring; the supervising physician documents medical necessity, assesses for contraindications (active infection, sepsis, live vaccine concerns), and records rationale if an unusual dose or medically complex circumstances occur.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Procedure or service subject to the outpatient PPS payment adjustment (placeholder) |